From the Research
Cagrisema is typically dosed at 2.4 mg once weekly via subcutaneous injection for adults with type 2 diabetes, as evidenced by the most recent and highest quality study 1. The dosing regimen for Cagrisema involves a gradual titration to minimize gastrointestinal side effects, starting with a lower dose and increasing over time.
- The medication is administered subcutaneously, and patients should rotate injection sites between the abdomen, thigh, or upper arm.
- The mean change in HbA1c from baseline to week 32 was greater with Cagrisema versus cagrilintide, but not versus semaglutide, as reported in the study 1.
- Cagrisema works by combining two mechanisms: it mimics GLP-1 (glucagon-like peptide-1) to reduce appetite and slow gastric emptying while also activating the cagrilintide pathway to enhance satiety signals.
- This dual action provides effective weight management and improves metabolic parameters, as demonstrated in the study 1. Key points to consider when prescribing Cagrisema include:
- Starting with a lower dose and gradually increasing to the maintenance dose of 2.4 mg weekly
- Rotating injection sites to minimize local reactions
- Storing the medication in the refrigerator until use and allowing it to warm to room temperature before injection
- Monitoring patients for gastrointestinal side effects and adjusting the dosing regimen as needed.